Abivax S.A.

🇫🇷France

Country: 🇫🇷France

Ownership: -

Employees: 61

Market Cap: $752.4M

Website

Introduction: Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis ...

Clinical Trials

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Phase 2

Not yet recruiting

Conditions: Moderately to Severely Active Crohn Disease

Interventions: Drug: Obefazimod
Other: Placebo

First Posted Date: 2024-06-13

Last Posted Date: 2024-08-02

Lead Sponsor: Abivax S.A.

Target Recruit Count: 212

Registration Number: NCT06456593

ABTECT - Maintenance

Phase 3

Recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: ABX464
Drug: Placebo

First Posted Date: 2022-09-10

Last Posted Date: 2024-08-07

Lead Sponsor: Abivax S.A.

Target Recruit Count: 1050

Registration Number: NCT05535946

Locations: 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
Wexner Medical Center, Columbus, Ohio, United States
🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

and more 547 locations

ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Phase 3

Recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: ABX464
Drug: Placebo

First Posted Date: 2022-08-18

Last Posted Date: 2024-07-26

Lead Sponsor: Abivax S.A.

Target Recruit Count: 612

Registration Number: NCT05507203

Locations: 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
Biopharma Informatic, LLC, Houston, Texas, United States
🇺🇸
MedOne Clinical Research LLC, Miami, Florida, United States

and more 245 locations

ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Phase 3

Recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: Placebo
Drug: ABX464

First Posted Date: 2022-08-18

Last Posted Date: 2024-07-26

Lead Sponsor: Abivax S.A.

Target Recruit Count: 612

Registration Number: NCT05507216

Locations: 🇺🇸
Ocala GI Research, Ocala, Florida, United States
🇺🇸
Sarkis Clinical Trials - Parent, Ocala, Florida, United States
🇺🇸
Iowa Digestive Disease Center, Clive, Iowa, United States

and more 270 locations

Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

Phase 2

Active, not recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: ABX464

First Posted Date: 2022-01-05

Last Posted Date: 2023-12-18

Lead Sponsor: Abivax S.A.

Target Recruit Count: 203

Registration Number: NCT05177835

Locations: 🇵🇱
Centrum Medyczne Plejady, Kraków, Poland
🇧🇪
UZ Leuven, Leuven, Belgium
🇵🇱
Trialmed CRS, Piotrkow Trybunalski, Poland

and more 5 locations

Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Caffeine
Drug: ABX464
Drug: Fluvoxamine

First Posted Date: 2021-11-16

Last Posted Date: 2022-01-05

Lead Sponsor: Abivax S.A.

Target Recruit Count: 59

Registration Number: NCT05121714

Locations: 🇬🇧
Simbec-Orion, Merthyr Tydfil, United Kingdom

Safety and Pharmacokinetics Study in Healthy Japanese Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: ABX464
Drug: Placebo

First Posted Date: 2021-09-02

Last Posted Date: 2023-01-26

Lead Sponsor: Abivax S.A.

Target Recruit Count: 48

Registration Number: NCT05032560

Locations: 🇯🇵
Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan

ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19

Phase 2

Terminated

Conditions: COVID-19

Interventions: Drug: Placebo
Drug: ABX464

First Posted Date: 2020-05-19

Last Posted Date: 2021-06-30

Lead Sponsor: Abivax S.A.

Target Recruit Count: 509

Registration Number: NCT04393038

Locations: 🇩🇪
Universitätsmedizin Mannheim Ruprecht-Karls-Universität Heid, Mannheim, Baden-Württemberg, Germany
🇧🇷
Instituto Nacional de Infectologia Evandro Chagas - FIOCRUZ Rio de Janeiro, Rio De Janeiro, Brazil
🇫🇷
Hôpital Saint-Antoine, Paris, France

and more 27 locations

Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: ABX464

First Posted Date: 2019-08-08

Last Posted Date: 2023-01-26

Lead Sponsor: Abivax S.A.

Target Recruit Count: 40

Registration Number: NCT04049448

Locations: 🇧🇪
Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
🇧🇪
UZ Gent, Gent, Belgium
🇧🇪
UZ Leuven, Leuven, Belgium

and more 21 locations

Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis

Phase 2

Conditions: Ulcerative Colitis

Interventions: Drug: ABX464

First Posted Date: 2019-07-17

Last Posted Date: 2021-12-22

Lead Sponsor: Abivax S.A.

Target Recruit Count: 217

Registration Number: NCT04023396

Locations: 🇩🇪
Medizinische Hochschule Hannover, Hanover, Germany
🇦🇹
AKH - Medizinische Universität Wien, Vienna, Austria
🇧🇾
Gomel Regional Clinical Hospital, Gomel, Belarus

and more 117 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy